CFP: A Protein Target for Cancer and Neurodegenerative Diseases

Target Name: CFP

NCBI ID: G5199

CFP: A Protein Target for Cancer and Neurodegenerative Diseases

CFP (Creatinine Fragment Peptide), also known as Proteolytic Enzyme Inhibitor (PEI) or Protease Inhibitor (PI), is a drug target (also known as biomarker) that has been shown to have potential in treating a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

CFP is a protein that is produced by the enzymeCreatinine Kinase (CK), which is found in most cells of the body. CK is responsible for breaking down the proteinCreatinine, which is a byproduct of muscle metabolism, and turning it into a toxic compound that can damage cells.

In cancer, CK is often overexpressed, which can lead to the breakdown of critical cellular structures and contribute to tumor progression. By inhibiting CK activity, CFP has been shown to have anti-tumor effects.

In neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases, CK is often misfolded and forms aggregates that are thought to contribute to the damage caused by these diseases. CFP has been shown to cross-react with these misfolded proteins and to have neuroprotective effects.

In autoimmune disorders, such as rheumatoid arthritis and multiple sclerosis, CK is often involved in the immune response and has been implicated in the development of these disorders. CFP has been shown to have anti-inflammatory effects and to promote the resolution of autoimmune diseases.

CFP has also been shown to have potential as a therapeutic agent in treating other diseases, including sepsis, heart failure, and acute respiratory distress syndrome (ARDS).

The development of CFP as a drug target began in the 1980s when researchers discovered that high levels of CK activity were associated with the death of brain cells in people with Alzheimer's disease. They then began to search for drugs that could inhibit CK activity and prevent the damage caused by this enzyme.

Since then, numerous compounds have been developed as potential CK inhibitors, including some that are currently in clinical trials. These compounds range in structure from small molecules to large drugs, and their efficacy has been tested in a variety of models, including cell-based assays, animal models, and clinical trials.

One of the most promising CK inhibitors is a compound called CFP-0122, which is currently being tested in clinical trials for the treatment of neurodegenerative diseases. In these trials, CFP-0122 has been shown to cross-react with the misfolded proteins that are thought to contribute to the damage caused by these diseases, and to have neuroprotective effects.

Another promising CK inhibitor is a compound called CFP-132, which is being tested for the treatment of cancer. In these trials, CFP-132 has been shown to inhibit the activity of CK and to have anti-tumor effects.

While the development of CFP as a drug target is an exciting area of research, there are also concerns about its potential side effects. CFP is a protein that is found in most cells of the body, so any drugs that are developed to inhibit CK activity could potentially affect a wide range of cells and organs.

Additionally, the use of CK inhibitors as therapeutic agents has been associated with a number of potential side effects, including nausea, vomiting, and diarrhea. In some cases, these side effects have been severe and have led to the discontinuation of clinical trials for these compounds.

Overall, the development of CFP as a drug target is an promising area of research that has the potential to treat a wide range of diseases. While further research is needed to fully understand the safety and effectiveness of CFP and its potential as a therapeutic agent, its development is an exciting and promising direction for future

Protein Name: Complement Factor Properdin

Functions: A positive regulator of the alternate pathway (AP) of complement (PubMed:20382442, PubMed:28264884). It binds to and stabilizes the C3- and C5-convertase enzyme complexes (PubMed:20382442, PubMed:28264884). Inhibits CFI-CFH mediated degradation of Complement C3 beta chain (C3b) (PubMed:31507604)

More Common Targets